Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE HIVES RELIEF versus CLARINEX D 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE HIVES RELIEF versus CLARINEX D 12 HOUR.
CETIRIZINE HYDROCHLORIDE HIVES RELIEF vs CLARINEX-D 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective peripheral H1-receptor antagonist. Competitively inhibits histamine at the H1 receptor, preventing histamine-mediated symptoms such as pruritus, sneezing, and rhinorrhea.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
Oral, 10 mg once daily; may be increased to 10 mg twice daily if needed.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 8-11 hours in healthy adults; increases to approximately 20 hours in renal impairment (CrCl <40 mL/min).
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; 10% is excreted in feces. Biliary excretion is minimal.
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant Combination